There are provided compositions comprising a purified cannabidiol (CBD) or a derivative thereof and an anti-inflammatory botanical extract, and methods of use thereof for the management of pain in a subject.

Microemulsions are described where hydrophobic liquid droplets are distributed in a continuous hydrophilic liquid phase. The described microemulsions may be thought of as modified oil-in-water (MOIW) microemulsions, where both the “oil” and “water” phases of the microemulsion are modified. The oil phase droplets of the MOIW microemulsion are modified with alcohol and can solubilize oil-soluble species, including cannabis extracts and terpenes. The polar continuous “water” phase of the MOIW microemulsion is modified with a sugar or sugar alcohol.

Microemulsions are described where hydrophobic liquid droplets are distributed in a continuous hydrophilic liquid phase. The described microemulsions may be thought of as modified oil-in-water (MOIW) microemulsions, where both the “oil” and “water” phases of the microemulsion are modified. The oil phase droplets of the MOIW microemulsion are modified with alcohol and can solubilize oil-soluble species, including cannabis extracts and terpenes. The polar continuous “water” phase of the MOIW microemulsion is modified with a sugar or sugar alcohol.

In order to make available the health-promoting and healing properties of curcumin to the human or animal organism, also in combination with at least one further active substance, a solubilizate consists of or contains a content of curcumin equal to or smaller than 10 wt %, preferably equal to or smaller than 7.5 wt %, most preferably 6 wt %, and at least one emulsifier with an HLB value in a range below 18, preferably between 13 and 18, namely polysorbate 80 or polysorbate 20 or a mixture of polysorbate 20 and polysorbate 80, with an average diameter of the curcumin-loaded micelles ranging from 5 nm to 40 nm, preferably from 6 nm to 20 nm, most preferably from 7 nm to 10 nm, for use in particular as a dietary supplement and/or pharmaceutical drug for treating and/or preventing diseases involving inflammation, cancer and other diseases.

Healthful supplements are described herein. For example, the supplements can include at least four of the following types of nutrients: an amino acid blend, a coconut extract, a vegetable glycerin extract, an alcohol blend, a cannabinoid blend, a hemp plant extract, a Boswellia serrata extract, a curcuma/turmeric blend, black cumin seed, an Artemisia ludoviciana extract, an Astragalus extract, a fenugreek extract, a mushroom extract blend, or any combination thereof.

Healthful supplements are described herein. For example, the supplements can include at least four of the following types of nutrients: an amino acid blend, a coconut extract, a vegetable glycerin extract, an alcohol blend, a cannabinoid blend, a hemp plant extract, a Boswellia serrata extract, a curcuma/turmeric blend, black cumin seed, an Artemisia ludoviciana extract, an Astragalus extract, a fenugreek extract, a mushroom extract blend, or any combination thereof.

Healthful supplements are described herein. For example, the supplements can include at least four of the following types of nutrients: an amino acid blend, a coconut extract, a vegetable glycerin extract, an alcohol blend, a cannabinoid blend, a hemp plant extract, a Boswellia serrata extract, a curcuma/turmeric blend, black cumin seed, an Artemisia ludoviciana extract, an Astragalus extract, a fenugreek extract, a mushroom extract blend, or any combination thereof.

The present invention relates to a dispersible composition of lipophilic compounds. The present invention particularly relates to a dispersible composition for increasing the bioaccessibility of lipophilic compounds derived from plant and/or synthetic source. Further the present invention relates to a process for preparing the dispersible composition as an oral dosage form.

The present invention relates to a dispersible composition of lipophilic compounds. The present invention particularly relates to a dispersible composition for increasing the bioaccessibility of lipophilic compounds derived from plant and/or synthetic source. Further the present invention relates to a process for preparing the dispersible composition as an oral dosage form.

A composition enriched with bisdemethoxycurcumin standardized to contain 20-80% w/w bisdemethoxycurcumin, 10-35% w/w demethoxycurcumin and 10-50% w/w curcumin. More specifically the invention discloses the potential of a composition comprising 20-80% w/w bisdemethoxycurcumin, 10-35% w/w demethoxycurcumin and 10-50% w/w curcumin in the management of nephrotoxicity in mammals. The composition further comprises a Nigella sativa extract standardised to contain not less than 2% w/w thymoquinone and about 0.01%-10% w/w thymohydroquinone.